Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1988 Oct;43(10):750–755. doi: 10.1136/thx.43.10.750

Effect of peptide histidine valine on cardiovascular and respiratory function in normal subjects.

E R Chilvers 1, C M Dixon 1, Y Yiangou 1, S R Bloom 1, P W Ind 1
PMCID: PMC461498  PMID: 3206383

Abstract

Non-adrenergic inhibitory nerves may have an important role in regulating airway calibre. A recently discovered peptide, peptide histidine valine, is a potent relaxer of airway smooth muscle in vitro and has been proposed as a possible neurotransmitter in this tissue. The cardiovascular and respiratory effects of graded infusions of this peptide (2.5-10 pmol kg-1 min-1) have been examined in six normal subjects in a placebo controlled, randomised double blind study. The mean (SEM) peak plasma concentration of peptide histidine valine during the highest infusion rate was 2392 (170) pmol/l, representing a 29 fold increase above the basal concentration. This was accompanied by flushing, a significant increase in heart rate of 28 (3.7) beats/min and skin temperature of 1.8 degrees (0.16 degrees) C, but no effect on systolic or diastolic blood pressure. Despite these high plasma concentrations of the peptide and the substantial tachycardia and increase in skin blood flow, there was no change in partial expiratory flow at 40% of vital capacity (Vp40) or in the airway response to inhaled histamine (geometric PD40 9.37 and 9.73 mumol during saline and peptide histidine valine infusion respectively). Although these findings provide no support for a physiological role of peptide histidine valine in controlling airway function in healthy subjects, important effects of locally released peptides in the vasoactive intestinal peptide family cannot be excluded.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J., Dixon C. M. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis. 1984 Aug;130(2):162–166. doi: 10.1164/arrd.1984.130.2.162. [DOI] [PubMed] [Google Scholar]
  2. Davis C., Kannan M. S., Jones T. R., Daniel E. E. Control of human airway smooth muscle: in vitro studies. J Appl Physiol Respir Environ Exerc Physiol. 1982 Nov;53(5):1080–1087. doi: 10.1152/jappl.1982.53.5.1080. [DOI] [PubMed] [Google Scholar]
  3. Dey R. D., Shannon W. A., Jr, Said S. I. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res. 1981;220(2):231–238. doi: 10.1007/BF00210505. [DOI] [PubMed] [Google Scholar]
  4. Doidge J. M., Satchell D. G. Adrenergic and non-adrenergic inhibitory nerves in mammalian airways. J Auton Nerv Syst. 1982 Mar;5(2):83–99. doi: 10.1016/0165-1838(82)90030-3. [DOI] [PubMed] [Google Scholar]
  5. Ghatei M. A., Springall D. R., Richards I. M., Oostveen J. A., Griffin R. L., Cadieux A., Polak J. M., Bloom S. R. Regulatory peptides in the respiratory tract of Macaca fascicularis. Thorax. 1987 Jun;42(6):431–439. doi: 10.1136/thx.42.6.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Morice A., Unwin R. J., Sever P. S. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet. 1983 Nov 26;2(8361):1225–1227. doi: 10.1016/s0140-6736(83)91272-2. [DOI] [PubMed] [Google Scholar]
  7. NANC nerves in airways. Lancet. 1986 Nov 29;2(8518):1253–1254. [PubMed] [Google Scholar]
  8. Palmer J. B., Cuss F. M., Warren J. B., Blank M., Bloom S. R., Barnes P. J. Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax. 1986 Sep;41(9):663–666. doi: 10.1136/thx.41.9.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Peatfield A. C., Richardson P. S. Evidence for non-cholinergic, non-adrenergic nervous control of mucus secretion into the cat trachea. J Physiol. 1983 Sep;342:335–345. doi: 10.1113/jphysiol.1983.sp014854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Richardson J., Béland J. Nonadrenergic inhibitory nervous system in human airways. J Appl Physiol. 1976 Nov;41(5 Pt 1):764–771. doi: 10.1152/jappl.1976.41.5.764. [DOI] [PubMed] [Google Scholar]
  11. Yiangou Y., Di Marzo V., Spokes R. A., Panico M., Morris H. R., Bloom S. R. Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. J Biol Chem. 1987 Oct 15;262(29):14010–14013. [PubMed] [Google Scholar]
  12. Yiangou Y., Requejo F., Polak J. M., Bloom S. R. Characterization of a novel prepro VIP derived peptide. Biochem Biophys Res Commun. 1986 Sep 30;139(3):1142–1149. doi: 10.1016/s0006-291x(86)80296-0. [DOI] [PubMed] [Google Scholar]
  13. Yiangou Y., Williams S. J., Bishop A. E., Polak J. M., Bloom S. R. Peptide histidine-methionine immunoreactivity in plasma and tissue from patients with vasoactive intestinal peptide-secreting tumors and watery diarrhea syndrome. J Clin Endocrinol Metab. 1987 Jan;64(1):131–139. doi: 10.1210/jcem-64-1-131. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES